Thymic epithelial tumors (TETs) are rare primary mediastinal tumors arising from thymic epithelium. Their rarity and complexity hinder investigations of their causes and therapy development. Here, we summarize the existing knowledge regarding medical treatment of these tumors, and thoroughly review the known genetic aberrations associated with TETs and the present status of potential biological treatments. Epidermal growth factor receptor (EGFR), stem-cell factor receptor, insulin-like growth factor-1 receptor (IGF1R), and vascular endothelial growth factors (VEGF-A, VEGF-B, and VEGF-2) are overexpressed in TETs. EGFR overexpression in TETs is associated with higher stage, and IGF1R overexpression has poor prognostic value. Data indicate that anti-IGF1R monoclonal antibodies, and inhibitors of angiogenesis, somatostatin receptors, histone deacetylase, mammalian target of rapamycin, and cyclin-dependent kinases may be active against TETs. Continued investigations in this field could lead to advancement of targeted and biological therapies for TETs.

Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors / D. Serpico, A. Trama, E.R. Haspinger, F. Agustoni, L. Botta, R. Berardi, G. Palmieri, P. Zucali, R. Gallucci, M. Broggini, G. Gatta, U. Pastorino, G. Pelosi, F. De Braud, M.C. Garassino. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 26:5(2015 May), pp. mdu527.838-mdu527.847. [10.1093/annonc/mdu527]

Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors

F. Agustoni;G. Pelosi;F. De Braud;
2015-05

Abstract

Thymic epithelial tumors (TETs) are rare primary mediastinal tumors arising from thymic epithelium. Their rarity and complexity hinder investigations of their causes and therapy development. Here, we summarize the existing knowledge regarding medical treatment of these tumors, and thoroughly review the known genetic aberrations associated with TETs and the present status of potential biological treatments. Epidermal growth factor receptor (EGFR), stem-cell factor receptor, insulin-like growth factor-1 receptor (IGF1R), and vascular endothelial growth factors (VEGF-A, VEGF-B, and VEGF-2) are overexpressed in TETs. EGFR overexpression in TETs is associated with higher stage, and IGF1R overexpression has poor prognostic value. Data indicate that anti-IGF1R monoclonal antibodies, and inhibitors of angiogenesis, somatostatin receptors, histone deacetylase, mammalian target of rapamycin, and cyclin-dependent kinases may be active against TETs. Continued investigations in this field could lead to advancement of targeted and biological therapies for TETs.
Biological agents; Chemotherapy; Targeted therapy; Thymic carcinoma; Thymic epithelial tumors; Thymoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Biomarkers, Tumor; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Signal Transduction; Thymus Neoplasms; Treatment Outcome; Molecular Targeted Therapy; Oncology; Hematology; Medicine (all)
Settore MED/06 - Oncologia Medica
ANNALS OF ONCOLOGY
http://annonc.oxfordjournals.org/
Article (author)
File in questo prodotto:
File Dimensione Formato  
838.full.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 126.61 kB
Formato Adobe PDF
126.61 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/426880
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 14
social impact